This Article Free upon publication Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneider, D. J. Articles by Sobel, B. E. Search for Related Content PubMed PubMed Citation Articles by Schneider, D. J. Articles by Sobel, B. E. Related Collections Anticoagulant mechanisms Arterial thrombosis Deep vein thrombosis Coagulation Platelet function inhibitors Thrombosis risk factors Platelets

(Circulation. 2007;116:305-315.)
© 2007 American Heart Association, Inc.

Contemporary Reviews in Cardiovascular Medicine

Conundrums in the Combined Use of Anticoagulants and Antiplatelet Drugs

David J. Schneider, MD; Burton E. Sobel, MD

From the Cardiology Division and Cardiovascular Research Institute, University of Vermont, Burlington.

Correspondence to Burton E. Sobel, MD, University of Vermont, Colchester Research Facility, 208 South Park Dr, Colchester, VT 05446. E-mail burton.sobel@uvm.edu

Key Words: anticoagulants • platelet aggregation inhibitors • hemorrhage • platelets • thrombosis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Medical pharmacological therapy typically targets a single process or agent. Examples include the selection of a specific antibiotic to suppress growth or viability of a specific bacterium, administration of a specific hormone to obviate a specific endocrinologic deficiency, and utilization of a specific chemotherapeutic agent selected to annihilate neoplastic cells of a specific type. By contrast, the use of anticoagulants and antiplatelet drugs deviates from this general principle because of several considerations: (1) inevitable interactions that link activation of platelets and activation of the coagulation cascade; (2) the effect of commonly used antithrombotics (eg, heparin and warfarin) on multiple factors in the coagulation cascade; and (3) profound amplification of a prothrombotic state of >5 orders of magnitude associated with activation. Accordingly, the concentration in blood of an antithrombotic agent that is sufficient to completely suppress its target under basal conditions may be totally insufficient in such suppression when the thrombotic system is activated. Conversely, if a concentration is sufficient to suppress the target under conditions of activation of the thrombotic system, a hemorrhagic diathesis may be induced under basal conditions. Thus, even when a patient has a single condition to be targeted with antithrombotic measures, the considerations that govern therapy are complex.

Numerous positive and negative feedback loops in the prothrombotic process¹ confer additional complexity. Important examples of positive loops include activation of coagulation factor (F) V and FVIII by thrombin with consequent augmentation of activation of generation of FXa through what has been called the intrinsic pathway, activation of . . . [Full Text of this Article]

This article has been cited by other articles:

				R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndrome J. Am. Coll. Cardiol., September 23, 2008; 52(13): 1095 - 1103. [Full Text] [PDF]